De-implementation of low value castration for men with prostate cancer: protocol for a theory-based, mixed methods approach to minimizing low value androgen deprivation therapy (DeADT)

[1]  B. Mahal,et al.  Receipt of definitive therapy in elderly patients with unfavorable‐risk prostate cancer , 2017, Cancer.

[2]  David A. Chambers,et al.  Application of discrete choice experiments to enhance stakeholder engagement as a strategy for advancing implementation: a systematic review , 2017, Implementation Science.

[3]  Jeremy M. Grimshaw,et al.  A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems , 2017, Implementation Science.

[4]  T. Skolarus,et al.  Optimizing veteran-centered prostate cancer survivorship care: study protocol for a randomized controlled trial , 2017, Trials.

[5]  R. Boland,et al.  The physician’s experience of changing clinical practice: a struggle to unlearn , 2017, Implementation Science.

[6]  G. Mann,et al.  Men's preferences and trade‐offs for prostate cancer screening: a discrete choice experiment , 2015, Health expectations : an international journal of public participation in health care and health policy.

[7]  R. DiPaola,et al.  Fifteen-year Outcomes Following Conservative Management Among Men Aged 65 Years or Older with Localized Prostate Cancer. , 2015, European urology.

[8]  Laura D. Scherer,et al.  Informed Decision Making , 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  S. Michie,et al.  Characterising an implementation intervention in terms of behaviour change techniques and theory: the ‘Sepsis Six’ clinical care bundle , 2015, Implementation Science.

[10]  M. Menon,et al.  Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer. , 2015, European urology.

[11]  R. Shankar,et al.  Description of anti-diabetic drug utilization pre- and post-formulary restriction of sitagliptin: findings from a national health plan , 2015, Current medical research and opinion.

[12]  N. Keating,et al.  Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer. , 2015, The Journal of urology.

[13]  David Richards,et al.  Complex Interventions in Health : An overview of research methods , 2015 .

[14]  Kenneth L Kehl,et al.  Association of Actual and Preferred Decision Roles With Patient-Reported Quality of Care: Shared Decision Making in Cancer Care. , 2015, JAMA oncology.

[15]  R. Jagsi,et al.  Shared Decision Making in Cancer Care: Does One Size Fit All? , 2015, JAMA oncology.

[16]  I. Graham,et al.  “Entrenched practices and other biases”: unpacking the historical, economic, professional, and social resistance to de-implementation , 2015, Implementation Science.

[17]  Susan Michie,et al.  Demystifying theory and its use in improvement , 2015, BMJ quality & safety.

[18]  S. Birken,et al.  Potential determinants of health-care professionals’ use of survivorship care plans: a qualitative study using the theoretical domains framework , 2014, Implementation Science.

[19]  Natalie J Gould,et al.  Application of theory to enhance audit and feedback interventions to increase the uptake of evidence-based transfusion practice: an intervention development protocol , 2014, Implementation Science.

[20]  Stavros Petrou,et al.  Discrete Choice Experiments in Health Economics: A Review of the Literature , 2014, PharmacoEconomics.

[21]  T. Skolarus,et al.  American Cancer Society prostate cancer survivorship care guidelines , 2014, CA: a cancer journal for clinicians.

[22]  A. Schuit,et al.  The preferences of users of electronic medical records in hospitals: quantifying the relative importance of barriers and facilitators of an innovation , 2014, Implementation Science.

[23]  Leila C. Kahwati,et al.  De-implementation of inappropriately tight control (of hypoglycemia) for health: protocol with an example of a research grant application , 2014, Implementation Science.

[24]  N. Keating,et al.  Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Michie,et al.  Using psychological theory to understand the challenges facing staff delivering a ward-led intervention to increase hand hygiene behavior: a qualitative study. , 2014, American journal of infection control.

[26]  Robert West,et al.  The Behaviour Change Wheel: A Guide To Designing Interventions , 2014 .

[27]  A. Dahan,et al.  De-implementation of expensive blood saving measures in hip and knee arthroplasties: study protocol for the LISBOA-II cluster randomized trial , 2014, Implementation Science.

[28]  E. Dusseldorp,et al.  Measuring determinants of implementation behavior: psychometric properties of a questionnaire based on the theoretical domains framework , 2014, Implementation Science.

[29]  E. Dusseldorp,et al.  Discriminant content validity of a theoretical domains framework questionnaire for use in implementation research , 2014, Implementation Science.

[30]  J. Ioannidis,et al.  Evidence-based de-implementation for contradicted, unproven, and aspiring healthcare practices , 2014, Implementation Science.

[31]  R. Lawton,et al.  Development of a theory-based instrument to identify barriers and levers to best hand hygiene practice among healthcare practitioners , 2013, Implementation Science.

[32]  C. Abraham,et al.  The Behavior Change Technique Taxonomy (v1) of 93 Hierarchically Clustered Techniques: Building an International Consensus for the Reporting of Behavior Change Interventions , 2013, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.

[33]  K. Bauer,et al.  Impact of formulary restriction with prior authorization by an antimicrobial stewardship program , 2012, Virulence.

[34]  S. Michie,et al.  Validation of the theoretical domains framework for use in behaviour change and implementation research , 2012, Implementation Science.

[35]  J. Francis,et al.  Theories of behaviour change synthesised into a set of theoretical groupings: introducing a thematic series on the theoretical domains framework , 2012, Implementation Science.

[36]  J. Grimshaw,et al.  Developing theory-informed behaviour change interventions to implement evidence into practice: a systematic approach using the Theoretical Domains Framework , 2012, Implementation Science.

[37]  B. McNeil,et al.  Understanding variation in primary prostate cancer treatment within the Veterans Health Administration. , 2012, Urology.

[38]  Mandy Ryan,et al.  Discrete choice experiments in health economics: a review of the literature. , 2012, Health economics.

[39]  Y. Kuo,et al.  Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States. , 2011, Urologic oncology.

[40]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[41]  Y. Kuo,et al.  Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. , 2010, Journal of the National Cancer Institute.

[42]  Y. Kuo,et al.  Reimbursement policy and androgen-deprivation therapy for prostate cancer. , 2010, The New England journal of medicine.

[43]  Alicia C. Bunger,et al.  Outcomes for Implementation Research: Conceptual Distinctions, Measurement Challenges, and Research Agenda , 2010, Administration and Policy in Mental Health and Mental Health Services Research.

[44]  M. Petticrew,et al.  Developing and evaluating complex interventions: the new Medical Research Council guidance , 2008, BMJ : British Medical Journal.

[45]  Dirk F Moore,et al.  Survival following primary androgen deprivation therapy among men with localized prostate cancer. , 2008, JAMA.

[46]  S. Krein,et al.  Management of chronic noncancer pain by VA primary care providers: when is pain control a priority? , 2008, The American journal of managed care.

[47]  A. D'Amico,et al.  Guideline for the management of clinically localized prostate cancer: 2007 update. , 2007, The Journal of urology.

[48]  Thomas J. Smith,et al.  Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Goodwin,et al.  Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. , 2006, Journal of the National Cancer Institute.

[50]  J. Goodwin,et al.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. , 2006, Archives of internal medicine.

[51]  Alec B. O’Connor,et al.  Eliminating analgesic meperidine use with a supported formulary restriction. , 2005, The American journal of medicine.

[52]  P. Walsh.  American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. , 2005, The Journal of urology.

[53]  C. Abraham,et al.  Making psychological theory useful for implementing evidence based practice: a consensus approach , 2005, Quality and Safety in Health Care.

[54]  J. Goodwin,et al.  Risk of fracture after androgen deprivation for prostate cancer. , 2005, The New England journal of medicine.

[55]  Rosemary K. Rushmer,et al.  Unlearning in health care , 2004, Quality and Safety in Health Care.

[56]  N. Sato,et al.  Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. , 2004, Urology.

[57]  S. Piñeros,et al.  A qualitative study to identify barriers and facilitators to implementation of pilot interventions in the Veterans Health Administration (VHA) Northwest Network. , 2004, Worldviews on evidence-based nursing.

[58]  P. Williamson,et al.  Design and analysis of pilot studies: recommendations for good practice. , 2004, Journal of evaluation in clinical practice.

[59]  Mandy Ryan,et al.  Discrete choice experiments in health care , 2004, BMJ : British Medical Journal.

[60]  A. Scott,et al.  What do hospital consultants value about their jobs? A discrete choice experiment , 2003, BMJ : British Medical Journal.

[61]  G. MacDonald,et al.  Transformative unlearning: safety, discernment and communities of learning. , 2002, Nursing inquiry.

[62]  M. Bassetti,et al.  The effect of formulary restriction in the use of antibiotics in an Italian hospital , 2001, European Journal of Clinical Pharmacology.

[63]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[64]  M. Bassetti,et al.  Impact of an antimicrobial formulary and restriction policy in the largest hospital in Italy. , 2000, International journal of antimicrobial agents.

[65]  P. Coudron,et al.  Hospital-wide Restriction of Clindamycin: Effect on the Incidence of Clostridium difficile-Associated Diarrhea and Cost , 1998, Annals of Internal Medicine.

[66]  A. Coldman,et al.  Effects of intermittent androgen suppression on the stem cell composition and the expression of the TRPM-2 (clusterin) gene in the Shionogi carcinoma , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[67]  S. M. Baboolal,et al.  Comment: Ketorolac Formulary Restriction and Usage Evaluation , 1992, The Annals of Pharmacotherapy.

[68]  D. Gianarkis.  Ketorolac Formulary Restriction and Usage Evaluation , 1991, DICP : the annals of pharmacotherapy.

[69]  Jennings Rh,et al.  Retrospective analysis of formulary restriction demonstrates significant cost savings. , 1991 .

[70]  D. Kreling,et al.  The Effects of an Internal Analgesic Formulary Restriction on Medicaid Drug Expenditures in Wisconsin , 1989, Medical care.

[71]  J. John,et al.  Effect of formulary restriction of cefotaxime usage. , 1985, Archives of internal medicine.

[72]  David C. Miller,et al.  Sharp Decline In Prostate Cancer Treatment Among Men In The General Population, But Not Among Diagnosed Men. , 2017, Health affairs.

[73]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[74]  Deborah Marshall,et al.  Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[75]  H. Nurnberg,et al.  Formulary Restriction of Selective Serotonin Reuptake Inhibitors for Depression , 2012, PharmacoEconomics.

[76]  T. H. van der Kwast,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[77]  David C Aron,et al.  Tailoring an intervention to the context and system redesign related to the intervention: A case study of implementing shared medical appointments for diabetes , 2008, Implementation science : IS.

[78]  D. Dillman.  Mail and internet surveys: The tailored design method, 2nd ed. , 2007 .

[79]  C. Burkhart.  And the beat goes on: formulary restriction, generic substitution, prior authorization, drug utilization, and now therapeutic interchange. , 2004, Journal of Drugs in Dermatology.

[80]  Mandy Ryan,et al.  Using discrete choice experiments to value health care programmes: current practice and future research reflections. , 2003, Applied health economics and health policy.

[81]  R. H. Jennings,et al.  Retrospective analysis of formulary restriction demonstrates significant cost savings. , 1991, Hospital formulary.

[82]  D. Kreling,et al.  Changes in market shares for internal analgesic products after a Medicaid formulary restriction. , 1988, Journal of pharmaceutical marketing & management.

[83]  M. Patton.  Qualitative research and evaluation methods , 1980 .